Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation
- PMID: 12698308
- DOI: 10.1007/s00228-003-0559-5
Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation
Abstract
Objective: The aim of this study was to develop routinely applicable limited sampling strategies for assessing cyclosporin (CsA) AUC(0-12 h), and possibly other exposure indices such as AUC(0-4 h) and C(max), in heart transplant patients over the first year post-transplantation.
Methods: First, the individual pharmacokinetics (PKs) of 14 adult heart-transplant patients receiving Neoral were assessed at three post-transplantation periods, at the end of the first week (W1), the third month (M3) and the first year (Y1). To fit blood concentrations, a PK model specially developed for oral CsA was applied. Second, two statistical methods were compared for AUC(0-12 h) estimation using a limited sampling strategy (maximum of three blood samples): multiple regression analysis (MR) and Bayesian estimation (BE).
Results: No significant difference was observed between the individual PK parameters at M3 and Y1, so population modelling was performed taking as a whole the concentration data collected at M3 and Y1. On the contrary, a significant difference ( P<0.05) was found for the C2/dose ratio between W1 and M3 and between W1 and Y1 (mean+/-SD =5.47+/-2.33; 7.78+/-1.05; 6.98+/-2.17 ml(-1 )for W1, M3 and Y1, respectively). Also, C(max)/dose and A were found significantly lower at W1 than at M3 ( P<0.01 and P<0.005, respectively), while lambda(1) was significantly higher at W1 than at both M3 and Y1 ( P<0.01). Using three sampling times (t0 h, t1 h and t3 h), BE allowed an accurate prediction of AUC(0-12 h) (mean bias =3.06+/-12.16%; +1.50+/-1.61%; and -0.20+/-11.42% at W1, M3 and Y1, respectively), AUC(0-4 h )and C(max). MR led to satisfactory estimation of AUC(0-12 h) using only two blood samples collected 2 h and 6 h post-dose (R=0.956-0.993; bias =-5.22 to +4.41; precision =6.38 to 9.90%), but this method is unable to estimate any other exposure index and requires strict respect of sampling times, contrary to BE.
Conclusion: Neoral monitoring based on full or abbreviated AUC is possible using BE or MR in heart transplant patients over the first year post-transplantation. BE provides a good description of the individual PK profiles and thus might be useful not only in case of potential discrepancies between C2 and clinical findings, but also for clinical trials aimed at finding optimum PK monitoring in heart recipients.
Similar articles
-
A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.Transplant Proc. 2004 Oct;36(8):2390-2. doi: 10.1016/j.transproceed.2004.08.025. Transplant Proc. 2004. PMID: 15561259
-
A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.Clin Ther. 2006 Jun;28(6):893-905. doi: 10.1016/j.clinthera.2006.06.015. Clin Ther. 2006. PMID: 16860172
-
Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.Transplant Proc. 2006 Sep;38(7):2132-4. doi: 10.1016/j.transproceed.2006.06.050. Transplant Proc. 2006. PMID: 16980022
-
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28. Transplant Rev (Orlando). 2011. PMID: 21190834
-
Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.Clin Pharmacokinet. 2000 Aug;39(2):117-25. doi: 10.2165/00003088-200039020-00003. Clin Pharmacokinet. 2000. PMID: 10976658 Review.
Cited by
-
Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.Clin Pharmacokinet. 2013 Apr;52(4):277-88. doi: 10.1007/s40262-013-0037-x. Clin Pharmacokinet. 2013. PMID: 23400901 Clinical Trial.
-
Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.Br J Clin Pharmacol. 2005 Jan;59(1):18-27. doi: 10.1111/j.1365-2125.2005.02200.x. Br J Clin Pharmacol. 2005. PMID: 15606436 Free PMC article.
-
Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies.Clin Pharmacokinet. 2005;44(12):1317-28. doi: 10.2165/00003088-200544120-00010. Clin Pharmacokinet. 2005. PMID: 16372829 Clinical Trial.
-
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.Clin Pharmacokinet. 2009;48(8):489-516. doi: 10.2165/11317240-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19705921 Review.
-
Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.Clin Pharmacokinet. 2008;47(4):277-84. doi: 10.2165/00003088-200847040-00005. Clin Pharmacokinet. 2008. PMID: 18336056 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous